Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia's Prana Charging Into Confirmatory Trials For Alzheimer's Drug That Looks To Alter Disease

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Melbourne-headquartered biotech Prana is gearing up to begin confirmatory trials for its lead molecule PBT2, an Alzheimer's disease treatment that has demonstrated surprising ability to reverse dementia symptoms
Advertisement

Related Content

Australia’s Prana Misses Primary Endpoint In POC Alzheimer’s Disease Trial; Stock Tanks
Australia’s Prana Biotech Phase II Data On Huntington’s Candidate Holds Investor Interest With More To Come
Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
Advertisement
UsernamePublicRestriction

Register

SC075559

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel